Adma Biologics (ADMA) Consolidated Net Income (2011 - 2025)
Adma Biologics (ADMA) posted Consolidated Net Income of -$133.3 million for Q4 2025, down 465.86% on a QoQ basis from $36.4 million in Q3 2025, and down 367.26% year-over-year from $49.9 million in Q4 2024.
Adma Biologics (ADMA) Consolidated Net Income (2011 - 2025) Analysis & Trends
Adma Biologics' Consolidated Net Income history runs 13 years deep, the most recent figure standing at -$133.3 million for Q4 2025.
- Quarterly Consolidated Net Income fell 367.26% year-over-year to -$133.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$35.7 million (down 126.34% YoY) and the FY2025 annual result came in at -$35.7 million, down 126.34% from the prior year.
- Consolidated Net Income was -$133.3 million for Q4 2025 at Adma Biologics, down from $36.4 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $49.9 million in Q4 2024 and bottomed at -$133.3 million in Q4 2025.
- A 5-year average of -$2.3 million and a median of -$6.6 million in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2024 — Consolidated Net Income surged 1299.96% — and 2025, when it sank 367.26%.
- Adma Biologics' Consolidated Net Income stood at -$25.1 million in 2021, then rose by 25.89% to -$18.6 million in 2022, then surged by 156.85% to $10.6 million in 2023, then jumped by 370.72% to $49.9 million in 2024, then plunged by 367.26% to -$133.3 million in 2025.
- Business Quant data shows ADMA's Consolidated Net Income at -$133.3 million in Q4 2025, $36.4 million in Q3 2025, and $34.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Adma Biologics | 1.98 Bn | 1.89 Bn | 88.82 Mn | -133.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -133.28 Mn |
| Sep 30, 2025 | 36.43 Mn |
| Jun 30, 2025 | 34.22 Mn |
| Mar 31, 2025 | 26.90 Mn |
| Dec 31, 2024 | 49.87 Mn |
| Sep 30, 2024 | 35.91 Mn |
| Jun 30, 2024 | 32.06 Mn |
| Mar 31, 2024 | 17.81 Mn |
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 2.57 Mn |
| Jun 30, 2023 | -6.37 Mn |
| Mar 31, 2023 | -6.79 Mn |
| Dec 31, 2022 | -18.64 Mn |
| Sep 30, 2022 | -14.89 Mn |
| Jun 30, 2022 | -13.75 Mn |
| Mar 31, 2022 | -18.17 Mn |
| Dec 31, 2021 | -25.15 Mn |
| Sep 30, 2021 | -17.73 Mn |
| Jun 30, 2021 | -18.82 Mn |
| Mar 31, 2021 | -18.34 Mn |